The fund was created in April 2017 in the form of a private Pricaf and targets companies active in the treatment of chronic diseases such as inflammatory, neurodegenerative, cardiovascular and cancer. The fund is aimed at Belgian companies as well as European "early stage" companies such as university spin-offs.
